In re Application of: Hiroaki Shizuya

Application No.: 09/896,509

Filed: June 28, 2001

Page 3

## In the claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

PATENT

Attorney Docket No.: CIT1390-1

Upon entry of the present amendment, the claims will stand as follows:

Please amend claims 1, 2, 14-16, 24, 25, 31, and 43 as follows:

1. (Currently Amended) A method for identifying an essential chromosomal gene in a haploid test organism, said method comprising:

constructing a BAC-carrying merodiploid test cell by transforming a wild-type haploid host cell whose genom[[e]]ic sequence is known, which is capable of being transformed by artificial means and is capable of undergoing DNA recombination, with a bacterial artificial chromosome (BAC) carrying a known segment of DNA of the haploid test organism, which segment is homologous with about 80% to 100% sequence identity to a known segment of chromosomal DNA in the host cell, and wherein replication of the BAC in the test cell is sensitive to an environmental condition that selectively prevents replication of the BAC in the host cell;

inserting randomly a bacterial transposon into the merodiploid test cell so as to disrupt function of a gene therein;

culturing one or more of the BAC-carrying merodiploid test cells in a suitable culture medium while introducing the environmental condition so as to transform the merodiploid test cells into haploid test cells; and

identifying one or more of the haploid test cells that contain transposon-mutagenized DNA in an essential chromosomal gene therein.

2. (Currently Amended) The method of claim 1 further comprising obtaining the identity of the essential chromosomal gene in the test organism by homology with a gene in the known segment of DNA locating a gene in the known segment of DNA of the haploid test organism that contains the transposon-mutagenized DNA.

Hiroaki Shizuya

Application No.: 09/896,509

Filed: June 28, 2001

Page 4

3. (Original) The method of claim 1 wherein the identifying involves selection of test cells that do not survive subjection to the environmental condition as having the transposon in an essential chromosomal gene therein.

Attorney Docket No.: CIT1390-1

- 4. (Original) The method of claim 1, wherein the transposon is Tn5 or Tn10.
- 5. (Original) The method of claim 4, wherein the transposon is operatively linked to a first antibiotic resistance gene.
- 6. (Original) The method of claim 5, wherein the BAC comprises a second antibiotic resistance gene, wherein the first and second antibiotic resistance genes convey resistance to two different antibiotic compounds.
- 7. (Previously Presented) The method of claim 6, wherein the first and second antibiotic resistance genes are selected to provide resistance to a pair of antibiotics selected from the group consisting of ampicillin, tetracycline, kanamycin, and chloramphenicol.
- 8. (Previously Presented) The method of claim 7, wherein the first and second antibiotic resistance genes provide resistance, respectively, to kanamycin and chloramphenicol.
- 9. (Original) The method of claim 6, wherein the identifying includes subjecting the test cells to both of the antibiotics to which the first and second antibiotic resistance genes provide resistance.
- 10. (Original) The method of claim 1, wherein the BAC is temperature sensitive for replication and the environmental condition is a temperature that is selectively non-permissive for replication of the BAC in the test cell.

Hiroaki Shizuya

Application No.: 09/896,509

Filed: June 28, 2001

Page 5

11. (Original) The method of claim 1, wherein the BAC is suppressor sensitive for

**PATENT** 

Attorney Docket No.: CIT1390-1

replication and the environmental condition is a suppressor that selectively suppresses

replication of the BAC in the test cell.

12. (Original) The method of claim 1, wherein the host cell is selected from the

group consisting of E. coli, Salmonellae, and B. subtilis.

13. (Original) The method of claim 12, wherein the host cell is *E. coli*.

14. (Currently Amended) The method of claim 1, wherein the identified essential

chromosomal gene has 100% sequence identity with a gene in the known segment of

DNA in the host cell.

15. (Currently Amended) The method of claim 1, wherein the identified essential

chromosomal gene has at least 90% sequence identity with a gene in the known segment

of DNA in the host cell.

16. (Currently Amended) The method of claim 1, wherein the identified essential

chromosomal gene has at least 80% sequence identity with a gene in the known segment

of DNA in the host cell.

17. (Original) The method of claim 1, wherein the BAC contains up to 100 genes of

the haploid test organism.

18. (Original) The method of claim 1, wherein the haploid test organism and the host

cell are the same species of prokaryote.

19. (Original) The method of claim 1, wherein a library of the BAC-carrying

merodiploid test cells is constructed such that the BACs in the library collectively contain

the entire genome of the haploid test organism.

Hiroaki Shizuya

Application No.: 09/896,509

Filed: June 28, 2001

Page 6

20. (Original) The method of claim 19, wherein the entire genome of the haploid organism is contained in about 50 to 100 merodiploid test cells that each contain a unique segment of the genome of the haploid test organism.

**PATENT** 

Attorney Docket No.: CIT1390-1

- 21. (Original) The method of claim 19, wherein the test cells in the library are simultaneously subjected to the environmental condition.
- 22. (Original) The method of claim 1, wherein sufficient of the merodiploid test cells are constructed to provide four-fold coverage of the entire genome of the haploid organism.
- 23. (Original) The method of claim 1, wherein the BAC in the merodiploid test cell is contained within a fosmid/cosmid.
- 24. (Currently Amended) The method of claim 23, wherein the fosmid/cosmid is packaged in lambda phage prior to insertion into the [[host]] merodiploid test cell.

In re Application of: Hiroaki Shizuya

Application No.: 09/896,509

Filed: June 28, 2001

Page 7

25. (Currently Amended) A method for screening bacterial genes in a pathogenic bacterium whose genome is known to select compounds with putative antibiotic activity, said method comprising:

PATENT

Attorney Docket No.: CIT1390-1

constructing a BAC-carrying merodiploid test cell by transforming a wild-type haploid host cell whose genom[[e]]ic sequence is known, which is capable of being transformed by artificial means and undergoing DNA recombination[[,]] with a BAC that carries a known segment of DNA of a haploid pathogenic bacterium, and wherein the BAC in the test cell is sensitive to an environmental condition that selectively prevents replication of the BAC in the test cell;

inserting randomly a transposon into the merodiploid test cell so as to disrupt function of a gene therein;

culturing one or more of the merodiploid test cells in a suitable culture medium while introducing the environmental condition;

identifying one or more test cells that do not survive subjection to the environmental condition as containing the transposon in an essential chromosomal gene therein;

obtaining locating the essential gene in the known segment of DNA of the pathogenic bacterium by identifying, by sequence comparison with the known genome of the host cell a gene in the known segment of DNA of the pathogenic bacterium in the haploid test cell that has been disrupted by the transposon; and

screening the essential gene obtained from the pathogenic bacterium or a bacterial protein encoded by the corresponding essential gene against putative antibiotic compounds to determine those compounds that bind to or interrupt function of the essential gene or the bacterial protein, wherein such a compound is a candidate antibiotic against the pathogenic bacterium.

- 26. (Original) The method of claim 25, wherein the transposon is Tn5 or Tn10.
- 27. (Original) The method of claim 25, wherein the transposon is operatively linked to a first antibiotic resistance gene.

Hiroaki Shizuya

Application No.: 09/896,509

Filed: June 28, 2001

Page 8

28. (Original) The method of claim 27, wherein the BAC comprises a second

**PATENT** 

Attorney Docket No.: CIT1390-1

antibiotic resistance gene.

29. (Previously Presented) The method of claim 28, wherein the first and second

antibiotic resistance genes are selected to provide resistance to a pair of antibiotics

selected from the group consisting of ampicillin, tetracycline, kanamycin, and

chloramphenicol.

30. (Previously Presented) The method of claim 29, wherein the first and second

antibiotic resistance genes provide resistance, respectively, to kanamycin and

chloramphenicol.

31. (Currently Amended) The method of claim 25, wherein the identifying locating

includes subjecting the test cells to the antibiotics to which the first and second antibiotic

resistance genes provide resistance.

32. (Original) The method of claim 25, wherein the BAC is temperature sensitive and

the environmental condition is a non-permissive temperature for replication of the BAC

in the test cells.

33. (Original) The method of claim 25, wherein the BAC is suppressor sensitive and

the environmental condition is a suppressor that selectively prevents replication of the

BAC in the test cells.

34. (Original) The method of claim 25, wherein the host cell is selected from the

group consisting of E. coli, Salmonellae, and B. subtilis.

35. (Original) The method of claim 34, wherein the host cell is *E. coli*.

Gray Cary\GT\6383466.1

Hiroaki Shizuya

Application No.: 09/896,509

Filed: June 28, 2001

Page 9

36. (Original) The method of claim 25, wherein the BAC contains up to 100 genes of the pathogenic bacterium.

**PATENT** 

Attorney Docket No.: CIT1390-1

- 37. (Original) The method of claim 25, wherein a library of the BAC-carrying merodiploid test cells is prepared such that the BACs in the library collectively contain the entire genome of the pathogenic bacterium.
- 38. (Original) The method of claim 37, wherein the entire genome is contained in about 50 to 100 merodiploid test cells that each contain a unique segment of the genome of the pathogenic bacterium.
- 39. (Original) The method of claim 38, wherein the test cells in the library are simultaneously subjected to the environmental condition.
- 40. (Original) The method of claim 25, wherein the candidate antibiotic is bactericidal.
- 41. (Original) The method of claim 25, wherein the bacterium is pathogenic in at least one mammalian species.
- 42. (Original) The method of claim 25, wherein the bacterium is pathogenic in at least one plant species.

Hiroaki Shizuya

Application No.: 09/896,509

Filed: June 28, 2001

Page 10

43. (Currently Amended) A method for identifying an essential chromosomal gene in a haploid test organism, said method comprising:

**PATENT** 

Attorney Docket No.: CIT1390-1

constructing a BAC carrying a known segment of DNA of the haploid test organism, which segment is homologous with about 80% to 100% sequence identity to a known segment of chromosomal DNA in a haploid host cell having a known genom[[e]]ic sequence, which is capable of being transformed by artificial means and [[is]] undergoing DNA recombination with the BAC;

inserting randomly a bacterial transposon into the BAC so as to disrupt function of a gene in the segment of chromosomal DNA;

introducing the BAC into the haploid host cell to create a merodiploid test cell; culturing the merodiploid test cell in a suitable culture medium such that the BAC in the test cell is sensitive to an environmental condition that selectively prevents replication of the BAC in the test cell;

identifying one or more BAC-carrying merodiploid test cells that do not survive in culture as containing the transposon in an essential chromosomal gene therein; and

obtaining the identity of the essential chromosomal gene by homology with determining which gene in the known segment of DNA of the haploid test cell inserted into the BAC that was introduced into the identified test cell was disrupted by the transposon.

- 44. (Original) The method of claim 43, wherein the transposon is Tn5 or Tn10.
- 45. (Original) The method of claim 43, wherein the transposon is operatively linked to a first antibiotic resistance gene.
- 46. (Previously Presented) The method of claim 43, wherein the transposon is inserted randomly into the BAC *in vitro* prior to introduction of the BAC into the test cell.

Hiroaki Shizuya

Application No.: 09/896,509

Filed: June 28, 2001

Page 11

47. (Previously Presented) The method of claim 46, wherein the known segment of

PATENT

Attorney Docket No.: CIT1390-1

DNA is linearized prior to introduction into the test cell.

48. (Original) The method of claim 43, wherein the host cell is an E. coli RecBC-

SbcBC quadruple mutant.

49. (Original) The method of claim 43, wherein the identifying includes subjecting

the test cells to the antibiotic to which the antibiotic resistance gene provides resistance.

50. (Original) The method of claim 43, wherein the host cell is selected from the

group consisting of E. coli, Salmonellae, and B. subtilis.

51. (Original) The method of claim 43, wherein the BAC contains up to 100 genes of

the test organism.

52. (Original) The method of claim 43, wherein a library of the BAC-carrying

merodiploid test cells is prepared such that the BACs in the library collectively contain

the entire genome of the test organism.

53. (Original) The method of claim 52, wherein the entire genome is contained in

about 50 to 100 merodiploid test cells that each contain a unique segment of the genome

of the test organism.

54. (Original) The method of claim 43, wherein the test organism is a pathogenic

bacterium.

Gray Cary\GT\6383466.1 104662-42

In re Application of:

Hiroaki Shizuya

Attorney Docket No.: CIT1390-1

Application No.: 09/896,509

Filed: June 28, 2001

Page 12

55. (Previously Presented) The method of claim 54, wherein the method further comprises screening an essential gene obtained from the pathogenic bacterium or a bacterial protein encoded thereby against putative antibiotic compounds to determine those compounds that bind to or interrupt function of the corresponding essential gene or the bacterial protein, wherein such a compound is a candidate antibiotic against the pathogenic bacterium.